The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
-
Neurocrine Clinical Site, Maitland, Florida, United States, 32751
Neurocrine Clinical Site, Tampa, Florida, United States, 33613
Neurocrine Clinical Site, Gaithersburg, Maryland, United States, 20877
Neurocrine Clinical Site, New York, New York, United States, 10029
Neurocrine Clincial Site, New York, New York, United States, 10128
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Neurocrine Biosciences,
Clinical Development Lead, STUDY_DIRECTOR, Neurocrine Biosciences
2027-07